Early Switch in Moderate ARDS (SWITCH-ARDS)
Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study
The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.
This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.
Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).
The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).
Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.
Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.
The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.
After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Apostolos - Alkiviadis Menis, MD, PhD
- Phone Number: +30 2413501280
- Email: menis.ap.alk@proton.me
Study Contact Backup
- Name: Demosthenes Makris, MD, PhD
- Phone Number: +30 2413501280
- Email: dimomakris@med.uth.gr
Study Locations
-
-
-
Larissa, Greece
- Recruiting
- Critical Care Department, University Hospital of Larisa
-
Contact:
- Apostolos Menis, MD, PhD
- Phone Number: +30 2413 501278
- Email: menis.ap.alk@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).
Description
Inclusion Criteria:
- Age ≥18 years
- Endotracheally intubated and receiving invasive mechanical ventilation
- Meets diagnostic criteria for acute respiratory distress syndrome
- PaO₂/FiO₂ ratio >100 and ≤200 mmHg
- Receiving controlled mechanical ventilation immediately before the transition trial
Exclusion Criteria:
- Implanted electrical cardiac or other device incompatible with electrical impedance tomography
- Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
- Contraindication to placement of an esophageal balloon catheter
- Active neuromuscular blockade at initiation of the transition trial
- Significant hemodynamic instability
- Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Protocolized Transition to Assisted Mechanical Ventilation
|
Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.
|
The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute). |
During the first thirty minutes of assisted ventilation.
|
|
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.
|
The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L). |
During the first thirty minutes of assisted ventilation.
|
|
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.
|
The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements. |
During the first thirty minutes of assisted ventilation.
|
|
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.
|
The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs). |
During the first thirty minutes of assisted ventilation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first thirty minutes of assisted ventilation.
|
The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography. |
During the first thirty minutes of assisted ventilation.
|
|
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.
|
The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms. |
During the first 30-minutes of assisted ventilation.
|
|
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.
|
The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography. |
During the first 30-minutes of assisted ventilation.
|
|
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.
|
The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values. |
During the first 30-minutes of assisted ventilation.
|
|
Differences in respiratory effort between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.
|
The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial. |
During the first 30-minutes of assisted ventilation.
|
|
Differences in respiratory effort between successful and failed transition to assisted ventilation.
Time Frame: During the first 30-minutes of assisted ventilation.
|
The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial. |
During the first 30-minutes of assisted ventilation.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Apostolos - Alkiviadis Menis, MD, PhD, General University Hospital of Larisa, University of Thessaly
- Study Director: Makris, MD, PhD, General University Hospital of Larisa, University of Thessaly
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SWITCH_MODERATE_ARDS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.